FDA Clearance Tracker · P170007-S007
DUROLANE
Last checked: Nov 20, 2026Latest source record: Nov 29, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Nov 29, 2020
Approved
Time to decision
89 days
Received Sep 1, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170007-S007
- Device name
- DUROLANE
- Applicant
- Bioventus, LLC
- Applicant location
- Durham, NC
- Received
- Sep 1, 2020
- Decided
- Nov 29, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P170007
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for the addition of a second supplier of the sodium hyaluronate raw material used in the manufacture of DUROLANE.
Source documents
Other decisions for Bioventus, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K253877 · Decided Aug 26, 2026 · 265 days after receipt
Device type: Stimulator, Peripheral Nerve, Implanted (Pain Relief) (GZF) · Neurology & Neurosurgery
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.